# A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

> **NCT00834808** · PHASE1 · COMPLETED · sponsor: **Labopharm Inc.** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tramadol HCl

## Key facts

- **NCT ID:** NCT00834808
- **Lead sponsor:** Labopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00834808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00834808, "A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00834808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*